MétaCan
Menu
Back to cohort

S2323 Addressing an Emerging Clinical Need: Nasal Metoclopramide's Impact on Diabetic Gastroparesis in Patients Taking GLP-1 Agonists

2024· article· en· W4403719993 on OpenAlexaff
David C. Kunkel, R.W. McCallum, Christopher Quesenberry, Mostafa Shokoohi, Paul Spin, Michael Cline

Bibliographic record

VenueThe American Journal of Gastroenterology · 2024
Typearticle
Languageen
FieldMedicine
TopicPharmacology and Obesity Treatment
Canadian institutionsEVERSANA (Canada)
Fundersnot available
KeywordsMedicineMetoclopramideGastroparesisGastroenterologyIntensive care medicineInternal medicineAnesthesiaGastric emptyingStomachVomiting

Abstract

fetched live from OpenAlex

Introduction: Diabetic gastroparesis (DGP) is a chronic upper gastrointestinal disorder characterized by delayed gastric emptying without mechanical obstruction, causing nausea, vomiting, and abdominal pain. Glucagon-like peptide 1(GLP-1) agonists, used to treat type 2 diabetes, can exacerbate these symptoms by delaying gastric emptying. This study compares healthcare resource utilization (HRU) in DGP patients treated with nasal (NMCP) vs oral metoclopramide (OMCP) with recent GLP-1 agonist use. Methods: A retrospective, matched cohort of NMCP- and OMCP-treated patients (257 per group) was derived from specialty pharmacy data and the Symphony Integrated Dataverse, an open claims database. Adult patients with a DGP diagnosis and ≥6 months pre- and post-index (treatment initiation) continuous data were included. Propensity score matching reduced imbalances in age, region, payor, Charlson Comorbidity Score, and 6-month pre-index hospitalization/emergency department (ED) use. Patients with a GLP-1 prescription filled ≤6 months pre-index were analyzed. Post-treatment all-cause and DGP-related HRU (gastroparesis, nausea, vomiting) were compared using a multivariable negative binomial regression model, with results as conditional incident rate ratios (cIRR) and 95% confidence intervals (CI). Results: The subgroup included 51 NMCP and 41 OMCP patients with a prior GLP-1 prescription. NMCP patients were slightly older (55.1 vs 53.1 years) and had more pre-index hospitalization/ED admissions (31.4% vs 19.5%). For NMCP patients, all-cause ED visits decreased by 55% (mean [SD]: 0.25 [1.13] post-index vs 0.55 [1.30] pre-index; P=0.063) and DGP-related ED visits decreased by 28% (mean [SD]: 0.18 [0.99] post-index vs 0.25 [1.28] pre-index; P=0.203).All-cause and DGP-related ED visits were 91% lower (cIRR: 0.09, 95% CI: 0.01, 0.42; P=0.001) and 89% lower (cIRR: 0.11, 95% CI: 0, 0.93; P=0.046) for NMCP vs OMCP. Furthermore, all-cause and DGP-related office visits were 41% lower (cIRR: 0.59, 95% CI: 0.37, 0.94; P=0.027) and 66% lower (cIRR: 0.34, 95% CI: 0.017, 0.65; P=0.001) for NMCP vs OMCP. All-cause clinic, outpatient, and inpatient visits showed similar trends favoring NMCP vs OMCP (Figure 1). Conclusion: In DGP patients with a prior claim for GLP-1, NMCP use was associated with numerically and significantly reduced all-cause and DGP-related HRU compared to pre-treatment utilization and OMCP-treated controls.Figure 1.: Comparison of healthcare resource utilization in glucagon-like peptide 1 agonist patients with diabetic gastroparesis.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.011
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.007
Threshold uncertainty score0.023

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.011
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0000.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0070.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.040
GPT teacher head0.410
Teacher spread0.370 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of GastroenterologySame topicPharmacology and Obesity TreatmentFrench-language works237,207